Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients - Scorecard - MDSpire
Advertisement
Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients
Clinical Scorecard: Efficacy and Safety Assessment of Long-Acting Versus Short-Acting Growth Hormone in Pediatric Isolated Growth Hormone Deficiency: A Systematic Review and Meta-Analysis of 16 Randomized Controlled Trials Involving 2,435 Children
At a Glance
Category
Detail
Condition
Key Mechanisms
Comparison of long-acting human growth hormone (LAGH) preparations, including PEG-LAGH, somatrogon, somapacitan, and lonapegsomatropin, with short-acting daily growth hormone (SA-GH).
Target Population
Care Setting
Key Highlights
LAGH showed a statistically significant improvement in first-year height standard deviation score (Ht-SDS) compared to SA-GH (p < 0.05).
PEG-LAGH subgroup demonstrated superior height velocity standard deviation score (HV-SDS) with a significant mean difference.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Regularly assess height velocity and IGF-1 levels during treatment, including specific thresholds for IGF-1.
Risks
Patient & Prescribing Data
LAGH offers improved adherence due to reduced injection frequency, but monitor for potential side effects.
